Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephanie Vertrees

Neurology Austin, TX Medical Doctor

NPI 1194941211 CMS profile 144754

8200 N Mopac Expy Ste 270, Austin, TX 78759

Open in the dashboard

General payments

$119,326

477 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephanie Vertrees of Austin, TX is reported in the CMS Open Payments database as having received $119,326 across 477 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33,016 67
2024 General $11,728 78
2023 General $7,148 85
2022 General $13,377 115
2021 General $32,541 77
2020 General $21,247 45
2019 General $270 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephanie Vertrees
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Stephanie Vertrees were reported at $33,016. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Stephanie Vertrees Neurology median Middle half National median
2019 $270 $474 $118–$2,177 $163
2020 $21,247 $367 $82–$2,309 $114
2021 $32,541 $438 $104–$2,547 $132
2022 $13,377 $442 $103–$2,388 $149
2023 $7,148 $464 $119–$2,312 $160
2024 $11,728 $468 $119–$2,323 $164
2025 $33,016 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $39,062 85 payments
  2. AbbVie, Inc. $34,749 133 payments
  3. Lilly USA, LLC $26,447 79 payments
  4. Amgen Inc. $10,335 38 payments
  5. Lundbeck LLC $4,590 21 payments
  6. Allergan Inc. $2,258 24 payments
  7. Teva Pharmaceuticals USA, Inc. $483 23 payments
  8. Biohaven Pharmaceutical Holding Company Ltd. $381 35 payments
  9. Biohaven Pharmaceuticals, Inc. $188 10 payments
  10. Axsome Therapeutics, Inc. $157 4 payments
  11. Other $675 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $94,809 63 payments
  2. Consulting Fee $13,110 11 payments
  3. Food and Beverage $8,473 395 payments
  4. Travel and Lodging $2,823 5 payments
  5. Education $112 3 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $33,001 77 payments
  2. EMGALITY $26,391 75 payments
  3. ZAVZPRET $23,599 32 payments
  4. NURTEC ODT Pain $15,420 66 payments
  5. AIMOVIG $10,402 40 payments
  6. QULIPTA $8,682 58 payments
  7. VYEPTI $4,523 18 payments
  8. NURTEC ODT Primary Care $569 45 payments
  9. REYVOW $506 27 payments
  10. AJOVY $466 22 payments
  11. Other $2,090 86 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

68

Median for Psychiatry & Neurology: 100

Drug cost

$33,255

Median for Psychiatry & Neurology: $2,986

Branded share of claims

33.8%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 23 $32,619
Sumatriptan Succinate Generic 15 $310
Prochlorperazine Maleate Generic 19 $199
Gabapentin Generic 11 $126

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZAVZPRET
  • PFIZER INC. $10,105
$10,105 — —
BOTOX
  • AbbVie, Inc. $326
$326 — —
EMGALITY
  • Lilly USA, LLC $173
  • Eli Lilly and Company $87
$260 — —
NURTEC ODT
  • PFIZER INC. $225
$225 23 —
VYEPTI
  • Lundbeck LLC $201
$201 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

477 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record